Our Science
We are experts in restoring homeostasis.
Graviton is redefining how we think about treating disease. We have developed a portfolio of selective ROCK2 inhibitors to selectively target fibrotic, autoimmune and CNS diseases across a range of organ systems.
What is ROCK2?
ROCK2, or Rho-associated coiled-coil kinase 2, is a crucial effector protein kinase in the Rho signaling pathway. It plays a significant role in regulating elementary cellular processes like cell contraction, migration, and adhesion. Understanding ROCK2's function is vital in the development of potential therapeutic modalities targeting disease, while maintaining homeostasis.
What is C6?
C6 is a component of the body's immune defense known as the complement system, which acts like a security team against harmful agents. It's not just a defender against infections; C6 also plays a role in certain neurological conditions. Our research at Graviton is turning the spotlight on C6, exploring its potential as a target for treating neurodegenerative diseases. Our leading-edge therapy involves a specially designed antibody that targets C6, aiming to control its activity. This could be a game-changer for managing diseases like myasthenia gravis and ALS, where C6's role is becoming increasingly recognized.
What is DYRK?
DYRK stands for dual-specificity tyrosine phosphorylation-regulated kinase, a type of protein that is crucial for cell signaling and function. The DYRK family, especially the DYRK1A and DYRK1B kinases, is implicated in several diseases, including type 1 diabetes, neurological disorders, and cancers. Abnormal activity of these kinases—whether too much or too little—can disrupt cellular balance, leading to disease. At Graviton, we are at the forefront of developing targeted inhibitors for these kinases. Our aim is to recalibrate their activity to normal levels, which could be key to innovative treatments for these challenging conditions.
Our Pipeline
Our translational research has led to the following indications.
